Zymeworks Enters Global License And Collaboration Agreement With Roche For Research, Development And Commercialization Of ZW209; Company Eligible For Upfront Payment Of $55M, With $40M Payment Upon Initiation Of Phase 1b Trial, And Additional Milestone Payments Of Up To $718M
Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040’sZymeworks will conduct the Phase 1a monotherapy clinical trial of ZW209 in
Zymeworks partnered with Roche, a giant pharmaceutical company. They will work together to develop and sell a new medicine. Zymeworks could receive $55 million upfront, then more money if certain milestones are reached. This means Roche believes in the drug's potential enough to invest seriously.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.